whether it represents value for money. A study was performed to evaluate the effectiveness of prophylaxis for all at risk patients in routine dental practice with published data from the United Kingdom. Methods-The risk of contracting infective endocarditis was calculated from published data to find (for high risk patients) both the annual number of deaths attributable to infective endocarditis and the number of high risk dental procedures performed without prophylaxis. Costs 16 The mean figure for these two years is 482 deaths. Of these about 15% are after dentistry. 1'7 Thus 72-3 deaths from IE a year will result from dental procedures. Not all of these, however, will have been in high risk patients. Bayliss patients undertaken in the absence of prophylactic cover is about 670 000 a year in England and Wales.
CALCULATING THE COSTS OF TREATING IE
Costs were calculated from an inspection of the notes of 63 patients who had had IE in Grampian over the decade 1980-90. Costs of a stay in hospital, valve replacement operations, and out-patient visits were supplied by the health authority. For survivors we only included those cases where there was bacteriological support for the clinical diagnosis. For the fatalities (patients not surviving a first episode of IE) we included patients whose certified cause of death included infective endocarditis and whose endocarditis had been confirmed either bacteriologically or by the presence of vegetations at post mortem examination. As many of the patients whose notes were inspected will continue to require care for many years, lifetime costs for their care were predicted statistically. As in normal accounting practice we discounted at 6% a year to adjust for the extended period during which costs were incurred.
Results

THE EFFECTS OF PROVIDING PROPHYLAXIS FOR HIGH RISK PATIENTS AFrER ALL AT RISK DENTAL PROCEDURES
As there are about 43A4 deaths from a total of 670 000 at risk people undergoing high risk procedures without prophylaxis, the risk of death for this group is about 0-65/10 000 procedures. As the mortality is about 20%'7 the risk of non-fatal IE is 2-6 cases/10 000 procedures.
Our estimates of the hospital cost of treating endocarditis are £3392 for a fatality and ,£11 831 for a survivor (at 1991/92 prices).
The figure shows the relation between costs and survival after endocarditis. The rising costs largely reflect the fact that some patients will need to undergo repeated valve replacement operations.
The net cost saving attributable to prophylaxis is the saving associated with the reduced number of people needing treatment after contracting IE less the cost of antibiotics and the treatment of allergic reactions (assumed to be in the region of £C500). The Relation between cost ofcare and survival after infective endocarditis. to induce a bacteraemia. This includes not only extraction but scaling, peridontal surgery, and more recently intraligamentary injection. 24 Our findings suggest that we should limit prophylaxis before dentistry to those patients undergoing dental extractions. As prophylaxis is currently provided to only about 50% of patients thought to be at high risk, primarily due to poor awareness by dentists as to which of their patients is at risk," savings might be achieved by extending antibiotic cover for dental extractions and reducing such cover for other high risk procedures.
If we were to achieve 100% prophylaxis cover before extractions for high risk patients, net savings over existing practice would amount to £2-5 million (principally from the reduction in the number of cases of endocarditis requiring treatment) and 56 lives would be saved each year in the United Kingdom.
If we were to discontinue the practice of providing prophylaxis before invasive dentistry other than extractions, we might anticipate savings throughout the United Kingdom of £1 9 million a year (principally from the reduction in the cost of providing antibiotics). The possible total savings by implementing such policies are therefore in the region of £4 4 million.
We must remember that our data might mask important differences. In the findings presented by Bayliss et al half the patients dying of infective endocarditis and with a known cardiac lesion had a prosthetic valve. '5 There are no reliable data on the prevalence of prosthetic valves within the population, but we expect the prevalence to be small in comparison with patients having a cardiac lesion but no prosthetic valve so the risk for patients with a prosthetic valve will be relatively high. Similarly patients who have survived an episode of IE seem to be at high risk. This suggests that prophylaxis is indicated for these groups of patients for any invasive dental procedure. Our results emphasise the importance of identifying as precisely as possible the patients and procedures for whom prophylaxis is being considered, something that is difficult as the underlying prevalence of various at risk abnormalities is not known.
SENSITIVITY ANALYSIS
Many of the assumptions used in determining the risk of contracting IE are a matter for debate. We have used figures that seem to us to be the most reliable; however, we also tested the robustness of our conclusions by investigating the effects of other figures quoted in relevant publications. Table 2 shows the effects of varying our assumptions. Sensitivity analysis is performed for both the case of providing prophylaxis for dental extractions and the case of invasive dental procedures other than extractions. We consider the effects of using assumptions both adverse and favourable to the case for prophylaxis. (A list of references can be supplied on demand.)
Our conclusions regarding extractions vary with different assumptions used in the calculation of risk, but in all cases the least favourable assumptions nevertheless result in a reduction in the number of fatalities.
Our estimates of the number of cases of IE a year in the United Kingdom are based on OPCS statistics for England and Wales for deaths from IE both mentioned and inferred. This gives a higher (although we believe realistic) estimate of the number of cases of IE than is sometimes quoted. Previous estimates have been based on notifications of death and are between 1000 and 1500 cases a year. Our estimate is equivalent to 2410 cases a year. We think that many cases are never diagnosed before death. In our unpublished review of cases in Grampian for the decade 1980-90 10 of 89 possible cases were diagnosed unexpectedly at postmortem examination. With postmortem examination rates for hospital death at about 20% (Dr K Kerr, Aberdeen Royal Hospitals Trust, personal communication) this will inevitably lead to a severe underestimate of cases. Nevertheless sensitivity analysis with a lower figure of 215 deaths a year still results in a saving of 2-54 lives and a saving of £264 000 to the health service for 10 000 cases given prophylaxis.
We use a figure of 20% for the mortality after IE. This may be considered by some to be high. As our calculations are based on the number of fatalities, had we used a lower figure for mortality, the number of survivors would have increased accordingly. A policy of prophylaxis would then provide the potential for even greater cost savings.
There are other consequences of reducing the incidence of IE that are extremely difficult to quantify, and which we have therefore omitted from our calculations. Importantly there are the suffering caused to survivors and the loss of economic output. The inclusion of these factors would serve to strengthen the case for expanding the use of prophylaxis.
Similarly There are no figures that we could find that would radically alter our results.
In conclusion we believe that prophylaxis to prevent IE in at risk patients undergoing extraction is cost effective even when the assumptions on which this conclusion is based are subject to stringent scrutiny. Consequently there is scope for expanding the use of prophylaxis in dental practice-for example, by improving communication between doctors and dentists so that the dentists are more aware of at risk patients,2' and perhaps also by giving prophylaxis to more elderly patients where the incidence of predisposing cardiac lesions is likely to be much higher. Alternatively, as most cases of IE associated with dental procedures are due to extractions, the case for prophylaxis for other procedures that Chan et al found that heparin inhibited growth in smooth muscle cells derived from patients with restenosis significantly less than those from controls. This aberrant response was not confined to cells derived from restenotic lesions: it was also found in smooth muscle cells cultured from apparently normal vessels from the same patient.
As the validity of animal models of restenosis is increasingly questioned, the importance of studying the disease in humans increases. Chan et al's data suggest that patients liable to restenosis have a generalised abnormality of smooth muscle cell proliferation in response to heparin, which may reflect a wider abnormality in the control of the growth of smooth muscle cells.
Prospective studies of the behaviour of human intimal smooth muscle cells might help to identify those at risk of restenosis and lead to therapeutic interventions to prevent restenosis.
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